Grades 3 to 5 toxicities (expressed as % of evaluable patients)
. | After CHOP; n = 87 . | . | . | After tositumomab/iodine I 131 tositumomab; n = 82 . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Toxicity by worst grade . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 3 . | Grade 4 . | Grade 5 . | ||||
| Neutropenia | 14 | 31 | 0 | 8 | 5 | 0 | ||||
| Thrombocytopenia | 1 | 0 | 0 | 9 | 2 | 0 | ||||
| Anemia | 3 | 0 | 0 | 0 | 2 | 0 | ||||
| Gastrointestinal | 6 | 1 | 0 | 1 | 0 | 0 | ||||
| Dermatologic | 0 | 0 | 0 | 2 | 0 | 0 | ||||
| Flu-like symptoms | 2 | 0 | 0 | 2 | 0 | 0 | ||||
| Pulmonary | 2 | 0 | 0 | 0 | 0 | 0 | ||||
| Infection | 11 | 1 | 0 | 2 | 0 | 0 | ||||
| Neurologic | 6 | 0 | 0 | 1 | 0 | 0 | ||||
| All endocrine | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cardiovascular | 4 | 1 | 0 | 0 | 0 | 0 | ||||
| Renal | 1 | 0 | 0 | 0 | 0 | 0 | ||||
| Sexual/reproductive | 2 | 0 | 0 | 1 | 0 | 0 | ||||
| Pain | 3 | 0 | 0 | 2 | 1 | 0 | ||||
| Immunologic | 0 | 1 | 0 | 0 | 1 | 0 | ||||
| Total | 30 | 34 | 0 | 28 | 10 | 0 | ||||
. | After CHOP; n = 87 . | . | . | After tositumomab/iodine I 131 tositumomab; n = 82 . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Toxicity by worst grade . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 3 . | Grade 4 . | Grade 5 . | ||||
| Neutropenia | 14 | 31 | 0 | 8 | 5 | 0 | ||||
| Thrombocytopenia | 1 | 0 | 0 | 9 | 2 | 0 | ||||
| Anemia | 3 | 0 | 0 | 0 | 2 | 0 | ||||
| Gastrointestinal | 6 | 1 | 0 | 1 | 0 | 0 | ||||
| Dermatologic | 0 | 0 | 0 | 2 | 0 | 0 | ||||
| Flu-like symptoms | 2 | 0 | 0 | 2 | 0 | 0 | ||||
| Pulmonary | 2 | 0 | 0 | 0 | 0 | 0 | ||||
| Infection | 11 | 1 | 0 | 2 | 0 | 0 | ||||
| Neurologic | 6 | 0 | 0 | 1 | 0 | 0 | ||||
| All endocrine | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cardiovascular | 4 | 1 | 0 | 0 | 0 | 0 | ||||
| Renal | 1 | 0 | 0 | 0 | 0 | 0 | ||||
| Sexual/reproductive | 2 | 0 | 0 | 1 | 0 | 0 | ||||
| Pain | 3 | 0 | 0 | 2 | 1 | 0 | ||||
| Immunologic | 0 | 1 | 0 | 0 | 1 | 0 | ||||
| Total | 30 | 34 | 0 | 28 | 10 | 0 | ||||